Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > liver fibrosis progression via VEGF-A

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Nov 18, 2020 12:09pm

88 Views

Post# 31922700

RE:RE:RE:RE:liver fibrosis progression via VEGF-A

https://pubmed.ncbi.nlm.nih.gov/26592322/

This paper on their publication list? From the little I understand it seems to be showing the same role that's being shown in the PPAR paper. And the take home message is along the lines of your last sentence. TGF-b1 has been identified to have a central role in NASH progression, it's elevated in inflamed livers and it's suppressed by a number of anti-NASH drugs. To see Egrifta treatment doing the same thing is highly encouraging.

Wino115 wrote:

I checked out Akeros research postings and one of the papers also mentions their Fibroblast Growth Factor (FGF) also downregulates TGFb1 and is mentioned as one of the key ways to lower liver fats. It's on their website under research. Given the success of just a few of these drugs on lowering liver fat more than 30% and they all seem to share a couple of these up and down regulations of similar genes, they must be important.

I'm happy to overlap with anything Akers also finds important given their industry leading Phase 2 results !

qwerty22 wrote:

Also just saw this abstract that's just out.

https://link.springer.com/article/10.1007/s13105-020-00777-7

PPAR drugs are another class of anti-NASH drugs. This paper suggests they work by affecting hepatic Stellate cells and down-regulating TGF-beta1 which is over-expressed during NASH. So potentially tesamorelin does what a PPAR drug does plus more, I think that's because GH/IGF-1 upregulates PPAR pathways as well as having other effects. I probably said this before but it's hard not to think of Egrifta as a combo drug treatment all in one molecules because it sits upstream of so many different processes.

jeffm34 wrote: TGF-β1 (transforming growth factor β1) was found to be mainly responsible for the up-regulation of CD147. Bioinformatic and experimental data suggest a functional link between CD147 expression and VEGF-A (vascular endothelial growth factor A)/VEGR-2 (VEGF receptor 2) signalling-mediated angiogenesis in fibrotic liver tissues.

Tesamorelin decreases TGF-B1 which appears to down regulate CD147 which decreases VEGF-A